Published on May 5, 2008 at 5:09 PM
NanoViricides, Inc said that its anti-HIV drug candidates demonstrated significant therapeutic efficacy in the recently completed preliminary animal studies.
The studies were performed at a Bio-Safety Level 3 Laboratory (BSL-3) facility in Boston, MA. These mouse model studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.
"Dr. Menon has indicated to us that the results of the study validate the Company's HivCide-I as a potential treatment for HIV/AIDS," said Eugene Seymour, MD, MPH, CEO of NanoViricides, adding, "Over the next several weeks, we expect to release additional study data." The Company's scientists are now designing the protocol for a follow up anti-HIV study to be performed at a major United States government research facility.
The Company also said that animal studies for its drug candidates against bird flu (H5N1) are due to be scheduled at a major United States government research facility. The company has previously reported that animal studies against Ebola would be undertaken following the success of in vitro studies. These studies are continuing.
NanoViricides, Inc. is using injectable nanoviricides for its initial HIV studies. Future plans call for the development of a long-acting anti-HIV skin patch. The Company feels that this delivery method will result in markedly improved patient compliance.
http://www.nanoviricides.com